ARTICLE | Company News
Varian Medical Systems, Cancer Research UK, The University of Auckland deal
May 30, 2011 7:00 AM UTC
The university granted Varian's Centella Therapeutics Inc. subsidiary exclusive, worldwide rights to CEN-209. Centella then partnered with Cancer Research to develop the hypoxia-activated cytotoxic p...